Zacks Investment Research·Jun 23, 2026
Xenon Pharmaceuticals Stock Gains 22% in Six Months: Here's WhyXENE's shares climb 22% in six months as azetukalner delivers strong phase III epilepsy data and advances across multiple late-stage studies.
Xenon Pharmaceuticals Inc.(XENE)Earnings, Financials & Key Ratios
XENE•NASDAQ
$63.37
Price updated Jul 7, 2026
AboutXenon Pharmaceuticals Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutics to treat patients with neurological disorders in Canada. Its clinical development pipeline includes XEN496, A Kv7 potassium channel opener that is Phase III clinical trials for the treatment of KCNQ2 developmental and epilepsy encephalopathy; and XEN1101, A Kv7 potassium channel opener, which is in Phase II clinical trial for the treatment of epilepsy and other neurological disorders. The company's product candidates also comprise NBI-921352, a selective Nav1.6 sodium channel inhibitor that is in Phase II clinical trials for the treatment of SCN8A developmental and epileptic encephalopathy, and other potential indications, including adult focal epilepsy; and XEN007, A central nervous system-acting calcium channel modulator, which is in Phase II clinical trials. It has a license and collaboration agreement with the Neurocrine Biosciences, Inc. to develop treatments for epilepsy; and with Flexion Therapeutics, Inc. to develop PCRX301 (XEN402, a Nav1.7 inhibitor) for the treatment of post-operative pain. Xenon Pharmaceuticals Inc. was incorporated in 1996 and is headquartered in Burnaby, Canada.Show more
- Revenue$8M
- EBITDA-$371M-33.9%
- Net Income-$346M-47.6%
- EPS (Diluted)-4.36-44.9%
- Gross Margin66.09%
- EBITDA Margin-4940.36%
- Operating Margin-4974.27%
- Net Margin-4612.13%
- ROE-51.76%-85.8%
XENE Price & Volume
Xenon Pharmaceuticals Inc. (XENE) stock price & volume — 10-year historical chart
Loading chart...
Clinical Development Costs Drive Persistent Cash Burn
Investment Thesis • Updated 2026Q1
VerdictNegative
Growth:Contracting
Profitability:Negative
Financial:Adequate
Cash Flow:Burning
Primary Risk:Clinical trial execution dependency
Key Thesis Takeaways
- Xenon Pharmaceuticals operates as a high-risk, pre-commercial biotechnology firm entirely dependent on the successful execution of late-stage clinical trials to generate future value.
- The company's financial profile is characterized by a lack of recurring revenue and an escalating R&D expenditure, which reached $88.5M in 2026Q1, necessitating continuous reliance on equity financing.
- Investors should monitor the company's ability to manage its $89.0M quarterly free cash flow burn rate against its current $545.9M cash position to ensure long-term operational viability.
Verdict Logic
the company's reliance on equity financing to cover widening quarterly operating losses exceeding $100M presents a significant dilution risk to shareholders until a commercial product is realized.
XENE Growth Metrics
Xenon Pharmaceuticals Inc. (XENE) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years-7.05%
5 Years-25.26%
3 Years-7.36%
TTM-100%
Profit CAGR
10 Years-
5 Years-
3 Years-
TTM-52.38%
EPS CAGR
10 Years-
5 Years-
3 Years-
TTM-45.51%
Return on Capital
10 Years-35.34%
5 Years-28.79%
3 Years-34.11%
Last Year-43.83%
XENE Recent Earnings
Xenon Pharmaceuticals Inc. (XENE) EPS & revenue vs analyst estimates — last 4 quarters
●Beat EPS 7/12 qtrs (58%)●Beat Revenue 2/12 qtrs (100%)
Q2 2026Latest
May 7, 2026Metric
Actual
Est
EPS
$1.17+0.0%
$1.17
Rev
—
$1M
Q1 2026
Feb 26, 2026Metric
Actual
Est
EPS
$1.31-9.2%
$1.20
Rev
—
$178,571
Q4 2025
Nov 3, 2025Metric
Actual
Est
EPS
$1.15+0.9%
$1.16
Rev
—
—
Q3 2025
Aug 11, 2025Metric
Actual
Est
EPS
$1.07-3.9%
$1.03
Rev
—
—
| Quarter | Date | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|---|
| Q2 2026Latest | May 7, 2026 | $1.17vs $1.17+0.0% | —vs $1M |
| Q1 2026 | Feb 26, 2026 | $1.31vs $1.20-9.2% | —vs $178,571 |
| Q4 2025 | Nov 3, 2025 | $1.15vs $1.16+0.9% | — |
| Q3 2025 | Aug 11, 2025 | $1.07vs $1.03-3.9% | — |
Based on last 12 quarters of dataView full earnings history →
Latest XENE News
Recent stock market news and headlines for Xenon Pharmaceuticals Inc. (XENE)
Peers Comparison
Key metrics vs top competitors for Xenon Pharmaceuticals Inc. (XENE)
| Company | Price | Market Cap | P/E Ratio | Rev Growth (1Y) | Net Margin | ROE | Div Yield |
|---|---|---|---|---|---|---|---|
| $63.37 | $5B | -14.53 | — | -4612.13% | -51.76% | — | |
| $323.95 | $9.36B | -24.03 | -100% | — | -43.02% | — | |
| $26.20 | $4.49B | 11.44 | 11.87% | 34.3% | 35.65% | — | |
| $89.20 | $7.4B | 11.47 | 114.51% | -22.58% | — | — | |
| $8.59 | $554.24M | -6.71 | -0.3% | -247.54% | -44.39% | — | |
| $2.76 | $364M | -11.50 | 1181.27% | -339.33% | -22.51% | — |
Compare XENE vs Peers
Xenon Pharmaceuticals Inc. (XENE) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
XENE SEC Filings & Documents
Xenon Pharmaceuticals Inc. (XENE) SEC filings — annual & quarterly reports (10-K, 10-Q)
8-K Announcements
6Material company update
May 7, 2026·SEC
Material company update
Apr 13, 2026·SEC
Material company update
Mar 13, 2026·SEC
10-K Annual Reports
310-Q Quarterly Reports
6Get notified when XENE posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
XENE Frequently Asked Questions
Xenon Pharmaceuticals Inc. (XENE) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
What is Xenon Pharmaceuticals Inc.'s revenue?
Xenon Pharmaceuticals Inc. (XENE) reported $7.5M in revenue for fiscal year 2025. This represents a 48% decrease from $14.3M in 2012.
Is XENE profitable?
Xenon Pharmaceuticals Inc. (XENE) reported a net loss of $383.2M for fiscal year 2025.
Dividend & Returns
What is XENE's return on equity?
Xenon Pharmaceuticals Inc. (XENE) has a return on equity (ROE) of -51.8%. Negative ROE indicates the company is unprofitable.
What is Xenon Pharmaceuticals Inc.'s free cash flow?
Xenon Pharmaceuticals Inc. (XENE) had negative free cash flow of $307.3M in fiscal year 2025, likely due to heavy capital investments.